Questions: How does Provectus compare to other biotechnology companies that have recently been bought out? Is there a chance for accelerated approval given Moffitt's immunology-related work?

Two questions from Mammon's list.

How does Provectus compare to other biotechnology companies that have recently been bought out?

This is a fluid answer, as valuations change based on company-specific, industry (biopharmaceuticals) and market factors, but two companies (or comparables) come to mind:

• BioVex, maker of OncoVex, was acquired by Amgen in January 2011 for up to $1 billion; $425 million in an upfront payment and $575 million in additional development and sales milestones; and

• Plexxikon, maker of the now approved Zelboraf (vemurafenib or PLX4032), was acquired by Daiichi Sankyo in February 2011 for up to $935; $805 million in an upfront payment and $135 million in other milestones.

During the RetailInvestorConferences.com webcast, Pete discussed the BioVex valuation of $1 billion as being the absolute floor for Provectus' acquisition valuation. BioVex was acquired about well into their pivotal MM Phase 3 trial. Enrollment in the OncoVEX trial commenced in April 2009, and was completed in Q2 2011. The Amgen deal was signed in January 2011 and closed in March. Interim analysis, which is expected to be performed at the end of this, only would be released at study completion in 2013.

Is there a chance for accelerated approval given Moffitt's immunology-related work?

The full scope of Moffitt's work (completed, in-process and in the near future) makes AA a real possibility. Pete addressed this topic today during the webcast. He also discussed getting the Fast Track designation following receipt of the SPA.